Cooperative Agreement U01AG084549
Award Date
9/24/24
Completion Date
8/31/27
Dollars Obligated
$3.2M
Federal Agency
National Institute on Aging
Awardee
Virogenics, Inc. (UFJ8JM4CXU22)
Federal Grant Program
93.866
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
This $2,432,649 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports Virogenics, Inc., a biotechnology company in San Diego, California, in advancing the development of CMS121, a novel small molecule drug candidate for treating Alzheimer's disease. The key products or services to be delivered under this grant include: Conducting 13-week toxicology studies in rats and dogs to enable longer-term clinical testing of CMS121 in human subjects with...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC provides $994,436.00 in funding to develop novel brain-penetrant drugs for therapeutic targeting of Alzheimer's disease. The research aims to investigate the role of the histone methyltransferase G9A in Alzheimer's disease pathogenesis and the mechanism of action for a brain-penetrant G9A-targeted drug, MS1262, which has shown potential to restore cognitive and affective functions...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Neucyte Inc. a $500,000 Project Grant to develop a nanoluciferase-based microphysiological systems platform for high-throughput screening of potential Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The project aims to create a scalable, reproducible "mini-brain" assembled organoid (assembloid) model using AD patient-derived and gene-edited induced...
This $1,044,855 Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund Nemalife Inc. to deliver high-throughput testing of anti-aging and FDA-approved drugs in genetically diverse invertebrate Alzheimer's disease models. Under the Aging Research program (CFDA 93.866), the awardee will screen 300 anti-aging compounds and 200 FDA drugs to identify candidates that improve neuronal aging and protect against protein misfolding diseases...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,968 to Hager Biosciences, LLC to further develop small molecule inhibitors of the Kv1.3 potassium channel as potential therapeutics for Alzheimer's disease. The key objectives are to: 1) complete in vitro characterization and initial pharmaceutical profiling of lead compound analogs; 2) initiate iterative lead optimization to improve potency and drug-like properties; and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,340,172 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop novel small molecule HDAC11 inhibitors as potential therapeutics for Alzheimer's disease (AD). The primary objectives are to: Explore structure-activity relationships (SAR) of the leading scaffold to create a new generation of HDAC11-selective inhibitors (Aim 1). Test the top compounds in...
The Project Grant award R43AG085863 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to support the development of a novel Alzheimer's disease therapeutic. The $504,732 award will enable Aphios Corp, a minority-owned biotechnology company, to nanoencapsulate an anti-CCR5 drug and evaluate its impact on brain inflammation and Alzheimer's disease in in vitro models and animal studies. The project aims to select promising...
The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
This $514,862 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of an on-chip functional assay to identify candidate microtubule-binding drugs for treating Alzheimer's Disease and related dementias (ADRDs). The award recipient, Neuroindx, a for-profit, woman-owned small business, will create an in vitro platform that replicates key features of the neuronal microtubule microenvironment. This on-chip assay will use generated...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $472,695 to 3D Bioanalytix, Inc., a woman-owned small business located in San Diego, CA, to develop a blood-based diagnostic test for detecting neurodegenerative diseases such as Alzheimer's and Parkinson's. The project aims to utilize a novel Covalent Protein Painting (CPP) technology platform to identify and differentiate the misfolded protein aggregates that characterize these...